Mizart 40 mg, 80 mg Tablets
PDF Leaflet Revision Date: 10 November 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of mild to moderate hypertension.
Dosage (summary)
40 mg once daily, may increase to 80 mg if needed.
Onset of Action / Duration
Onset: 3 hours, Duration: 24 hours
Special Populations
- Elderly population: No adjustment needed
- Renal impairment: No adjustment for mild to moderate
- Hepatic impairment: Max 40 mg for mild to moderate
Pregnancy & Breastfeeding
Not recommended in pregnancy; discontinue if pregnancy occurs. Avoid in breastfeeding.
Key Drug Interactions
- Increased hypotensive effect with other antihypertensives
- Lithium toxicity risk
- NSAIDs may reduce antihypertensive effect
Contraindications
- Hypersensitivity to telmisartan
- History of angioedema
- Severe renal impairment
- Bilateral renal artery stenosis
- Severe hepatic impairment
Common side effects
- Dizziness
- Hypotension
- Hyperkalaemia
- Fatigue
- Headache
Counselling Points
- Monitor blood pressure regularly
- Avoid potassium supplements
- Report any signs of hypotension or dizziness
Serious warnings
- Risk of severe hypotension in renal artery stenosis
- Monitor potassium levels in renal impairment
- Potential for acute renal failure
Important Disclaimer
The Mizart 40 mg, 80 mg Tablets professional information leaflet below is the property of Mylan and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
